Turnover at Novartis was $12.3 billion in the third quarter, up by 1% from a year earlier, as gains in sales volumes were partially offset by a fall in prices and generic competition for the legacy medicines Afinitor and Exjade. The pattern was similar for the first nine months of the year when sales rose by 2% to $35.9 billion.
